Dr. Bridges is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8000 5 Mile Rd
Ste 305
Cincinnati, OH 45230Phone+1 513-232-3500Fax+1 513-624-2704
Education & Training
- TriHealth (Bethesda North Hospital)Residency, Family Medicine, 2011 - 2013
- Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 2008 - 2009
- TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 2003 - 2006
- University of Cincinnati College of MedicineClass of 2003
Certifications & Licensure
- CO State Medical License 2019 - 2025
- OH State Medical License 2003 - 2025
- NH State Medical License 2024 - 2024
- NC State Medical License 2020 - 2022
- ME State Medical License 2020 - 2021
- American Board of Family Medicine Family Medicine
Publications & Presentations
PubMed
- 183 citationsMK-1775, a novel wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cellsKathleen Bridges, Hiroshi Hirai, Carolyn A. Buser, Colin Brooks, Huifeng Liu
Clinical Cancer Research. 2011-09-01 - 27 citationsABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stressAdrienne Howard, Kathleen Bridges, Raymond E. Meyn, Joya Chandra
Cancer Chemotherapy and Pharmacology. 2009-04-29 - 42 citationsNiraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.Kathleen Bridges, Carlo Toniatti, Carolyn A. Buser, Huifeng Liu, Thomas A. Buchholz
Oncotarget. 2014-06-09
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: